证券代码：600004 证券简称：白云机场 公告编号：2025－041 关于公司收到仲裁决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 案件所处的仲裁阶段：撤回仲裁申请 广州白云国际机场股份有限公司 一、基本情况 "中海智"、"被申请人"）签订《F、G 岛行李检查设备合同》(以 下简称"合同）"。在调试及使用过程中，申请人认为合同目的无法 实现，向仲裁机构请求裁决解除合同并赔偿相关损失（详见公司 2024 年 12 月 3 日披露的《关于公司提请仲裁的公告》（公告编号： 申请书》。 二、本次仲裁决定情况 （一）同意申请人撤回仲裁申请； （二）本案受理费 0 元(申请人已预缴 170035 元，退回 170035 元)、处理费 25505 元(申请人已预缴 51011 元，退回 25506 元)由申 请人承担。 三、对公司本期利润或期后利润等的影响 ? 上市公司所处的当事人地位：申请人 广州白云国际机场股份有限公司（以下简称"公司"、 "申请人"） 近日收到广州仲裁委员会《决定书》 （（2024 ...

Core Viewpoint - Emergent BioSolutions Inc. has secured a contract modification to deliver Vaccinia Immune Globulin Intravenous (Human) (VIGIV) to the U.S. Department of Health and Human Services for smallpox preparedness, highlighting the company's ongoing partnership with the U.S. government [1][2]. Group 1: Contract and Partnership - The contract modification involves additional doses of VIGIV, a treatment for complications arising from smallpox vaccination, under an existing 10-year contract with the Administration for Strategic Preparedness and Response (ASPR) [1]. - This modification follows a recent contract amendment for Botulism Antitoxin Heptavalent (BAT) with ASPR, indicating a broader collaboration between Emergent and the U.S. government in public health preparedness [2]. Group 2: Product Information - VIGIV is indicated for treating complications due to vaccinia vaccination, including severe generalized vaccinia and eczema vaccinatum, but is not indicated for postvaccinial encephalitis [3][4]. - The product has specific contraindications, including isolated vaccinia keratitis and severe allergic reactions to human globulins [4]. Group 3: Safety Information - Important safety information for VIGIV includes potential interactions with glucose monitoring systems, which may lead to falsely elevated blood glucose readings [3]. - Common adverse reactions reported in clinical trials for VIGIV include headache, nausea, rigors, and dizziness, with more than 10% of patients experiencing these effects [6].